# HORIZON 1 (NCT05170204)

> A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: alectinib; entrectinib
- Indication: unresectable stage III non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05170204
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Alectinib; Entrectinib; Durvalumab
- Enrollment: 68
- Primary outcome: Progression-free Survival (PFS), as Determined by Blinded Independent Central Review (BICR) per Response Evaluation Criterial in Solid Tumors Version 1.1 (RECIST V1.1)

## Indexed commentary on HORIZON 1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 4
- X threads: 3
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=horizon-1-nct05170204

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05170204", "email": "<work email>"}; the inbox owner confirms by the emailed link.